Hyloris Pharmaceuticals SA (FRA:52U)

Market Cap	223.44M +41.5%
Revenue (ttm)	8.46M +30.4%
Net Income	-6.41M
EPS	-0.24
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	180
Average Volume	72
Open	7.28
Previous Close	7.46
Day's Range	7.28 - 7.96
52-Week Range	4.54 - 8.08
Beta	n/a
RSI	61.39
Earnings Date	Mar 26, 2026

About Hyloris Pharmaceuticals

Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative pain, the opioid crisis, and acute pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the human papilloma virus; and Sotalol IV to treat atrial fibrillation. It also develops Aspirin IV and HY-074 IV to reduce the risk of morbidity and mortal...

• Industry: Pharmaceutical Preparations
• Founded: 2012
• Employees: 50
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 52U

Financial Performance

In 2024, Hyloris Pharmaceuticals's revenue was 9.76 million, an increase of 159.64% compared to the previous year's 3.76 million. Losses were -6.34 million, -58.76% less than in 2023.